Medical device and MedTech insights, news, tips and more

Implantable Organ Developer Miromatrix Raises Additional $15.7M in Series B Funding

July 12, 2018


July 12, 2018 – Press Release by Miromatrix Medical

Miromatrix Medical Inc. is excited to announce it recently raised $15.7 million in Series B-2 funding, surpassing its goal of $10 million. As part of the round, Miromatrix also welcomed its first large strategic investor, a multibillion-dollar health care company. The additional funding supports the company’s mission to bioengineer transplantable organs and save lives by eliminating the organ transplant waiting list, as well as the continued commercialization of Miromatrix’ novel acellular products based on perfusion decellularization.

“The closing of our Series B-2 round marks a significant milestone for us and brings us one step closer to our vision of eliminating the organ transplant waiting list,” says Jeff Ross , Ph.D., CEO of Miromatrix. “Not only does it signify the mounting interest in Miromatrix by large companies, it also highlights the growing excitement around our technology, products and progress.”

Through a breakthrough process of perfusion decellularization and recellularization developed at the University of Minnesota, scientists at Miromatrix are engineering fully functioning porcine livers and kidneys with the ultimate goal of developing patient-specific human organs. The company continues to build on its acellular products and the recently reported successful liver re-endothelialization studies where Miromatrix demonstrated functional liver vasculature by maintaining long-term vascular patency of its engineered liver grafts in a porcine model.  This demonstration of functional vasculature moves the company closer to its goal of creating lifesaving human organs.

Miromatrix is proceeding with preclinical functional evaluation of its bioengineered livers at the Mayo Clinic in Rochester, MN. The company is targeting the initiation of human clinical studies for its transplantable liver program as early as Q4 2020, with a bioengineered kidney to follow shortly after.

See More at the Source: Miromatrix Raises $15.7 Million in Series B-2 Funding, Welcomes Large Strategic Investor — MIROMATRIX MEDICAL Inc

Press Release by Miromatrix Medical

A Speciality Recruiting Firm Exclusively Servicing The Medical Device Industry

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.


More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.